Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q-Line BiotechNSE:QLINE -1.12%14 Receivables Turnover is 5.76 as of Mar. 2025. GuruFocus rates NSE:QLINE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Q-Line Biotech ranks better than 52.89% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Q-Line Biotech's Revenue for the
six
months ended in Mar. 2025 was ₹3,138 Mil. Q-Line Biotech's average Accounts Receivable for the
six
months ended in Mar. 2025 was ₹545 Mil.
Hence, Q-Line Biotech's Receivables Turnover for the
six
months ended in Mar. 2025 was 5.76.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Q-Line Biotech Receivables Turnover Related Terms
Q-Line Biotech Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech Receivables Turnover Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
Receivables Turnover
5.53
6.85
5.76
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
Receivables Turnover
5.53
6.85
5.76
NSE:QLINE vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Q-Line Biotech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech (NSE:QLINE) has a Receivables Turnover of 5.76 as of Mar. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Q-Line Biotech and its competitors. According to the industry distribution chart, Q-Line Biotech ranks #383 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 47.1%.
Is Q-Line Biotech's Receivables Turnover too high?
Q-Line Biotech's current Receivables Turnover is 5.76. The Medical Devices & Instruments industry median Receivables Turnover is 5.60. Q-Line Biotech's value of 5.76 is 2.9% above this industry median. Based on the distribution chart, Q-Line Biotech ranks #383 out of 813 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Q-Line Biotech has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #383 out of 813 companies for Receivables Turnover. This puts Q-Line Biotech in the upper half of its industry. The industry median Receivables Turnover is 5.60. Q-Line Biotech's value of 5.76 is 2.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.60, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-Line Biotech's current Receivables Turnover of 5.76 is 2.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current Receivables Turnover is 5.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Receivables Turnover of 5.76. The current Receivables Turnover is 5.76 and 2.9% above the Medical Devices & Instruments industry median of 5.60. Q-Line Biotech's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Receivables Turnover is 5.76 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
14GF Score
Get the complete analysis for NSE:QLINE
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 
